Trade Names:Thymoglobulin- Powder for injection 25 mg vials
Mechanism of action is not fully understood. Possible mechanisms include the following: T-cell Cl from the circulation and modulation of T-cell activation, homing, and cytotoxic activities.
The t ½ is 2 to 3 days.
Treatment of acute allograft rejection in renal transplantation.
Acute viral illness; hypersensitivity to leporine proteins; previous hypersensitivity to anti-thymocyte globulin.
IV 1.5 mg/kg/day for 7 to 14 days using a high-flow vein. Infuse over a minimum of 6 h for first infusion and over at least 4 h for subsequent doses.Dosage AdjustmentAdults
IV Reduce 50% if the WBC is between 2,000 and 3,000 cells/mm 3 or if the platelet count is between 50,000 and 75,000 cells/mm 3 . Consider stopping treatment if the WBC falls below 2,000 cells/mm 3 or platelets below 50,000 cell/mm 3 .
Store unopened vials in refrigerator (36° to 46°F). Protect from light and freezing. Use reconstituted vials within 4 h. Diluted infusion solution must be used immediately. Discard any unused solution. Do not save unused solution for future use.
Risk of infection may increase.
May interfere with rabbit antibody-based immunoassays and with cross-match or panel-reactive antibody cytotoxicity assays.
Hypertension (37%); tachycardia (27%).
Headache (40%); asthenia (27%); malaise (13%); dizziness (9%).
Abdominal pain (38%); diarrhea, nausea (37%).
Leukopenia (57%); thrombocytopenia (37%).
Fever (63%); chills (57%); pain (46%); infection (37%); peripheral edema (34%).
Monitor patient for signs of anaphylaxis or severe allergic reaction. Discontinue therapy and immediately notify health care provider if noted. Be prepared to treat appropriately.CBC
Ensure CBC and differential are determined at baseline and periodically during course of therapy.Lymphocyte count
Ensure lymphocyte count (total lymphocyte and/or T-cell subsets) is monitored during treatment to assess degree of T-cell depletion.
Category C .
Safety and efficacy not established.
Anaphylaxis may occur.
Human anti-rabbit antibodies develop in 68% of patients.
Local irritation or phlebitis may occur. Refer to your institution specific protocol.
Ensure that potential value of antiviral, antibacterial, antiprotozoal, and/or antifungal prophylaxis has been evaluated.
Copyright © 2009 Wolters Kluwer Health.